Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Fineline Cube Sep 9, 2026
Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services

Fineline Cube Nov 8, 2024

Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in...

Company Deals

Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development

Fineline Cube Nov 8, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...

Policy / Regulatory

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

Fineline Cube Nov 8, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Civil Affairs (MCA) have jointly...

Company Deals

Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology

Fineline Cube Nov 8, 2024

Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD

Fineline Cube Nov 7, 2024

Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Deals

Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody

Fineline Cube Nov 7, 2024

China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the...

Company Deals

Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a...

Company Deals

Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered...

Company Deals

Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings

Fineline Cube Nov 7, 2024

Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into...

Company

I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024

Fineline Cube Nov 7, 2024

US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD,...

Company

Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth

Fineline Cube Nov 7, 2024

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...

Company Deals

Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...

Company Medical Device

Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth

Fineline Cube Nov 7, 2024

Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Drug

HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024

Fineline Cube Nov 7, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...

Company Deals

Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives

Fineline Cube Nov 7, 2024

German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the...

Company Deals

Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development

Fineline Cube Nov 7, 2024

US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...

Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Company Drug

Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Fineline Cube Nov 7, 2024

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...

Company Drug

Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Posts pagination

1 … 323 324 325 … 718

Recent updates

  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.